Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Newron Pharmaceuticals Release: Ralfinamide Uniquely Shows Analgesic Effects In A Central Pain Model
9/11/2009
Milan, Italy – September 11, 2009 – Newron Pharmaceuticals SpA, a research and
development company focused on novel CNS and pain therapies, today announced
positive results from a preclinical study showing that ralfinamide has statistically significant
analgesic benefits against spontaneous chronic pain in an experimental model of central
pain. The study was conducted by Professor Ze’ev Seltzer, Canada Senior Research
Chair in Genetics of Pain, University of Toronto, Canada, and was presented yesterday
(September 10, 2009) at the Sixth International Congress of the European Federation of
IASP Chapters (EFIC), Lisbon, Portugal, September 9-12, 2009.
Highlights
· The efficacy of ralfinamide in a preclinical model of central pain provides
evidence that its analgesic effects in chronic pain operates on central
nervous system targets, in addition to its known peripheral mechanisms
· Ralfinamide’s unique ability to affect central targets widens its broad
spectrum of analgesic mechanisms, supporting its therapeutic potential
for alleviating Neuropathic Low Back Pain (NLBP) in the ongoing
SERENA Phase IIb/III clinical trial
· The new data suggest that ralfinamide may be effective in central pain
syndromes
The study showed that ralfinamide significantly suppressed spontaneous pain behavior,
expressed as self mutilation of the denervated hindpaw of a rodent, providing evidence
that ralfinamide is a centrally acting analgesic. These effects were recorded both when
ralfinamide was administered orally twice daily for one week before the surgery and
stopped thereafter (‘preemptive analgesia’ regimen), as well as when it was administered
only for 42 days postoperatively (‘palliative analgesia’ regimen). Analgesic effects were still
noted 21 days after stopping drug administration on day 42. In this model of central pain,
ralfinamide uniquely showed significant superiority compared to placebo, while pregabalin,
used as an active control, failed to show significant benefits compared to placebo.
“Due to the CNS origin of pain in this rodent model, the analgesic effects of ralfinamide
must have targeted mechanisms of neuropathic pain in the CNS”, said professor Ze’ev
Seltzer, the leading investigator of the study “The CNS target of this compound is yet to be
discovered, but chronic alterations in the function of neurons and glial cells in the CNS are
a seminal part of the development and maintenance of neuropathic pain in rodent models
and in many pain syndromes in humans, including Neuropathic Low Back Pain, where
ralfinamide is being evaluated in a Phase IIb/III clinical trial. Moreover, these new findings
open the potential for new therapeutic perspectives for ralfinamide in central pain
syndromes that are known to be refractory to current analgesics“ he added.
About Neuropathic Low Back Pain (NLBP)
Neuropathic Low Back Pain is by far the most common clinical emergence of neuropathic
pain (about 50% of patient prevalence and about 60% of diagnoses). About 55 million
patients in the USA, Europe and Japan experience NLBP. So far no drugs have been
approved for the treatment of this indication.
About Central Pain
Central pain syndrome is a neurological condition caused by damage to, or dysfunction of
the central nervous system (CNS), which includes the brain, brainstem, and spinal cord.
This condition can be produced by different causes such as stroke, brain or spinal cord
trauma, avulsion injuries that tear nerve roots from the spinal cord, multiple sclerosis,
tumours, epilepsy, congenital malformations, and more. A large number of patients
worldwide are affected by central pain, with substantial impact on the quality of life, mood,
sleep, cognition, social relations, work and domestic activities, etc. Central pain is usually
treated with antidepressants, anticonvulsants, and opioids; treatments which provide
partial pain relief at best, and which are often associated with major side-effects.
About Ralfinamide
Ralfinamide is a unique new chemical entity that is believed to mediate its potent analgesic
effect through the inhibition of sodium channels, incl. Nav. 1.7, N-type Calcium channels
and NMDA receptors. It is currently in Phase IIb/III development for Neuropathic Low Back
Pain.
About Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A. (www.newron.com) is a biopharmaceutical company focused on
novel therapies for diseases of the Central Nervous System and pain. Newron is undertaking
phase III trials with safinamide for the treatment of Parkinson’s disease (PD) in conjunction with its
partner, Merck Serono, which has exclusive worldwide rights to develop, manufacture and
commercialize the compound in PD, Alzheimer’s disease, and other therapeutic applications.
Newron recently initiated SERENA, a potentially pivotal study with ralfinamide in patients with
Neuropathic Low Back Pain (NLBP). There are no approved drugs for the treatment of NLBP, an
indication experienced by about 55 million patients in the USA, Europe and Japan. Newron is
headquartered in Bresso, near Milan, Italy. The company is listed at SIX Swiss Exchange, trading
symbol NWRN.
The poster presented at EFIC is downloadable at:
http://www.newron.com/presentationandfactsheet.asp
|
|
|
|
|
|
|
|
|